Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Wellington Shields & Co. LLC


Share on StockTwits

Wellington Shields & Co. LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,474 shares of the biopharmaceutical company’s stock after selling 1,231 shares during the period. Wellington Shields & Co. LLC’s holdings in Gilead Sciences were worth $435,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Federated Hermes Inc. lifted its position in shares of Gilead Sciences by 133.1% during the third quarter. Federated Hermes Inc. now owns 5,142,381 shares of the biopharmaceutical company’s stock worth $324,947,000 after purchasing an additional 2,936,687 shares in the last quarter. BlackRock Inc. raised its holdings in Gilead Sciences by 1.7% in the third quarter. BlackRock Inc. now owns 117,783,804 shares of the biopharmaceutical company’s stock valued at $7,442,757,000 after acquiring an additional 1,949,534 shares in the last quarter. DekaBank Deutsche Girozentrale raised its holdings in Gilead Sciences by 106.0% in the third quarter. DekaBank Deutsche Girozentrale now owns 1,679,176 shares of the biopharmaceutical company’s stock valued at $104,808,000 after acquiring an additional 863,916 shares in the last quarter. KAMES CAPITAL plc raised its holdings in Gilead Sciences by 170.5% in the fourth quarter. KAMES CAPITAL plc now owns 1,304,717 shares of the biopharmaceutical company’s stock valued at $75,905,000 after acquiring an additional 822,466 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in Gilead Sciences by 4,195.2% in the fourth quarter. Assenagon Asset Management S.A. now owns 818,801 shares of the biopharmaceutical company’s stock valued at $47,703,000 after acquiring an additional 799,738 shares in the last quarter. 76.36% of the stock is currently owned by institutional investors and hedge funds.

In related news, EVP Brett A. Pletcher sold 1,975 shares of the stock in a transaction that occurred on Wednesday, February 10th. The stock was sold at an average price of $67.41, for a total value of $133,134.75. Following the transaction, the executive vice president now owns 28,832 shares in the company, valued at $1,943,565.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.13% of the company’s stock.

A number of analysts have weighed in on the stock. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell dropped their target price on shares of Gilead Sciences from $75.00 to $72.00 in a report on Tuesday, December 22nd. Guggenheim upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating in a research report on Monday, January 4th. UBS Group started coverage on shares of Gilead Sciences in a research report on Wednesday, October 28th. They set a “neutral” rating and a $61.00 price objective for the company. BMO Capital Markets reduced their price objective on shares of Gilead Sciences from $64.00 to $62.00 and set a “market perform” rating for the company in a research report on Wednesday, December 16th. Finally, JPMorgan Chase & Co. restated a “hold” rating on shares of Gilead Sciences in a research report on Tuesday, December 8th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and twelve have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $94.93.

Shares of NASDAQ GILD traded down $0.76 during mid-day trading on Tuesday, reaching $63.35. The company had a trading volume of 278,487 shares, compared to its average volume of 8,977,984. The stock has a fifty day moving average of $65.08 and a two-hundred day moving average of $63.01. The company has a debt-to-equity ratio of 1.65, a quick ratio of 3.15 and a current ratio of 3.25. The company has a market capitalization of $79.41 billion, a price-to-earnings ratio of 66.09, a PEG ratio of 0.67 and a beta of 0.51. Gilead Sciences, Inc. has a 12-month low of $56.56 and a 12-month high of $85.97.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, February 4th. The biopharmaceutical company reported $2.19 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.04. Gilead Sciences had a return on equity of 37.77% and a net margin of 5.48%. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.06 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 30th. Investors of record on Monday, March 15th will be issued a $0.71 dividend. The ex-dividend date is Friday, March 12th. This represents a $2.84 dividend on an annualized basis and a yield of 4.48%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.68. Gilead Sciences’s dividend payout ratio is currently 44.30%.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: What is a Fibonacci Channel?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.